Novel Compounds as Serine Protease Inhibitors
OwnerKaspar Zimmermann, Daniel Kaspar Baeschlin +1inventors
InventorsKaspar Zimmermann, Daniel Kaspar Baeschlin, Saliha Moussaoui
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds of formula (I) wherein the substituents are as defined in claim 1; to compositions comprising said compounds and to their use as pharmaceutical agents, in particular as inhibitors of serine proteases.
Claims14
A compound of formula (I)
- wherein
- m is 0, 1, 2, 3, 4 or 5;
- p is 0 or 1;
- each R1 is independently selected from halogen, alkyl, haloalkyl, alkoxy, haloalkyloxy;
- and
- cycloalkyl;
- T is selected from optionally substituted aryl, optionally substituted alkyl, hydrogen, halogen, alkoxy, haloalkyloxy, COO-alkyl, and aryloxy;
- or a pharmaceutically acceptable salt or N-oxide thereof;
- with the exception of 1-(3-amino-4-phenyl-butyl)-pyrrolidine-2-carboxylic acid methyl ester.
(canceled)
A pharmaceutical composition comprising a compound of formula (I)
- wherein
- m is 0, 1, 2, 3, 4 or 5;
- p is 0 or 1;
- each R1 is independently selected from halogen, alkyl, haloalkyl, alkoxy, haloalkyloxy;
- and cycloalkyl;
- T is selected from optionally substituted aryl, optionally substituted alkyl, hydrogen, halogen, alkoxy, haloalkyloxy, COO-alkyl, and aryloxy;
- or a pharmaceutically acceptable salt or N-oxide thereof;
- and one or more pharmaceutically acceptable diluents or carriers.
A pharmaceutical combination comprising a compound of formula (I)
- wherein
- m is 0, 1, 2, 3, 4 or 5;
- p is 0 or 1;
- each R1 is independently selected from halogen, alkyl, haloalkyl, alkoxy, haloalkyloxy;
- and cycloalkyl;
- T is selected from optionally substituted aryl, optionally substituted alkyl, hydrogen, halogen, alkoxy, haloalkyloxy, COO-alkyl, and aryloxy;
- or a pharmaceutically acceptable salt or N-oxide thereof;
- and one or more co-agents.
11-13. (canceled)
A method for treating or preventing a serine protease-related disease or disorder in a subject comprising administering a therapeutically effective amount of a compound of formula (I)
- wherein
- m is 0, 1, 2, 3, 4 or 5;
- p is 0 or 1;
- each R1 is independently selected from halogen, alkyl, haloalkyl, alkoxy, haloalkyloxy;
- and cycloalkyl;
- T is selected from optionally substituted aryl, optionally substituted alkyl, hydrogen, halogen, alkoxy, haloalkyloxy, COO-alkyl, and aryloxy;
- or a pharmaceutically acceptable salt or N-oxide thereof.
Dependencies are inferred from the claim text.